Health Headlines: Novartis Win, Weight Loss Boosts, and More
Global health highlights include a court pausing a generic version of a heart drug, Novo Nordisk's weight loss trial success, FDA-approved cancer therapy, U.S. healthcare regulatory concerns, and Mozambique's abortion controversy impacting an AIDS program.
A U.S. appeals court has granted Novartis a temporary pause on the release of a generic version of its heart-failure drug, Entresto, as the court reviews a longer ban request. The decision holds off MSN Pharmaceuticals' launch of its product.
In Germany, authorities plan to end an emergency ordinance put in place to prevent foot-and-mouth disease, as the agriculture ministry reports stability with no new cases detected. The German agriculture minister confirmed the isolated nature of incidents.
Novo Nordisk reveals promising results from a late-stage trial of high-dose semaglutide, which achieved an impressive 20.7% weight loss in patients. The trial involved 1,407 participants, underscoring the potential of Wegovy in addressing obesity.
(With inputs from agencies.)
- READ MORE ON:
- health
- Novartis
- Entresto
- weight loss
- Novo Nordisk
- FDA
- cancer therapy
- AIDS program
- WHO
- bird flu
ALSO READ
FDA Shakeup: Vaccine Official’s Exit Sends Biotech Stocks Plummeting
Shakeup in Federal Health: FDA Vaccine Chief's Resignation Sparks Market Turmoil
FDA in Turmoil: Leadership Shakeup Amid Tobacco Policy Controversies
Health Briefs: Major FDA Moves, Lawsuit Updates, and AI Innovations
Supreme Court Ruling Supports FDA in Vaping Regulations
Google News